Clinical Impact of Pharmaceutical Consultations in Patients Treated for Chronic Obstructive Pulmonary Disease at Home

Clinical Impact of Pharmaceutical Consultations in Patients Treated for Chronic Obstructive Pulmonary Disease at Home

The implementation of pharmaceutical consultations in the city or at the hospital could modify the occurrence of exacerbations related to chronic obstructive pulmonary disease after return of the patient to his home.

Inclusion Criteria:

• The patient has signed the consent form.
• The patient is affiliated to a health insurance programme
• The patient is at least 18 years old (≥).
• The patient is admitted to complete hospitalization (for patients in the "Hospital and Control" groups).
• The patient is diagnosed with stage 2 to 4 Chronic Obstructive Pulmonary Disease. The diagnosis as well as the stage of the disease are validated by a pulmonologist at the facility.
• The patient has one or more inhaler devices to treat Chronic Obstructive Pulmonary Disease.
• The patient returns to his / her home when discharged from hospital (for patients in the "Hospital and Control" groups).
• The patient is available for a follow-up of 12 months.

Exclusion Criteria:

• The subject participates in another interventional study.
• The subject is in an exclusion period determined by a previous study.
• The patient is under safeguard of justice.
• The subject refuses to sign the consent.
• It is not possible to give the patient (or his/her trusted-person) informed information.